| URL | https://www.biopharmadive.com/news/vector-biomed-l |
| Source | BioPharmaDive |
| Date Published | 01/31/2023 |
| Author Name | Gwendolyn Wu |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Vector BioMed |
| Parent company | Vector BioMed |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Capital investment ($): | 15 |
| City reshored to: | Gaithersburg |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma, lentiviral vectors |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |